Sign in
Taking people in South KoreaNo phase

Safety of Luspatercept in Korean Patients With Blood Disorders

Studies real-world safety of luspatercept in Korean adults with myelodysplastic syndrome or beta thalassemia.

Key facts

Who runs it
Bristol-Myers Squibb
Where
Seoul, South KoreaSee the 2 sites
Trial code
Registry title
A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
Status
Recruiting
People taking part
104 people, planned
Started
25 Mar 2024
Expected to end
21 Dec 2027
Type of study
Observational
Treatments tested
  • Luspatercept
Record updated
6 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in Korea with myelodysplastic syndrome (MDS) or beta thalassemia who will be treated with luspatercept as approved in Korea. It watches how safe the drug is in real life.

Age
19 years or older
Sex
All sexes can join.

Main reasons for not taking part

  • Luspatercept prescribed for a use not approved in the Republic of Korea
  • Luspatercept is contraindicated, as set out in the Korean prescribing information

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Adult participants 19 years of age or older
  • Participants who will be treated with luspatercept according to the approved label in the Republic of Korea
  • Participants who sign the informed consent form

Who cannot take part

  • Participants for whom luspatercept is contraindicated as clarified in the Korean prescribing information approved by the Ministry of Food and Drug Safety
  • Participants who are prescribed luspatercept for therapeutic indications not approved in the Republic of Korea

Where in South Korea

  • Novotech Laboratory Korea Co., Ltd.Seoul, South KoreaContact: South Korea Generic Country, Site 0002Taking people
  • SeoulHospital not named in the registryNo longer taking part

About the trial

What the trial wants to find out

The purpose of this observational study is to assess the real-world safety of luspatercept in Korean participants with myelodysplastic syndrome (MDS) or beta thalassemia. Investigators will enroll participants who will begin treatment with at least 1 dose of luspatercept.

The group in the trial

  • Participants with myelodysplastic syndrome or beta thalassemia who will begin luspatercept treatment

    Treatment: Luspatercept

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Reblozyl® (Luspatercept) Post-Marketing Surveillance in Korean Patients With Myelodysplastic Syndrome or Beta Thalassemia
Plain-language title
Safety of Luspatercept in Korean Patients With Blood DisordersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 November 2024